Koreaticker.
Stock profile

Celltrion stock (068270.KS)

Biosimilars, close copies of existing antibody drugs, plus newer drugs such as Zymfentra

Prices as of Nov 13, 2026 · Financials: 12 months to June 2026

₩214,000≈ $158.52

No NYSE or Nasdaq listingAlso: Korea ETFs

068270 · Korea Exchange · As of Nov 13, 2026 close, ₩1,350 per dollar

Seoul ticker068270.KS
US listingNo NYSE or Nasdaq listing
Share price (close)₩214,000 (about $159)
Price dateNov 13, 2026
1-year change+15%
52-week range₩159,400 – ₩236,861
Market valueabout $36.2B
Revenue, 12 months to Jun 2026$3.6B
Operating profit, same period$1.1B (31.7% margin)
P/E, same period31.0x
P/B (Jun 30, 2026 book value)2.73x
Closest US peerTeva (TEVA)

Quick answers

FAQ

What is the ticker for Celltrion stock?

Celltrion trades on the Korea Exchange in Seoul under the code 068270, often written 068270.KS. It has no NYSE or Nasdaq listing.

Can you buy Celltrion stock in the US?

Not on a US exchange. Since May 2026, Interactive Brokers has let eligible clients buy Celltrion's Seoul shares directly, in won, during Korean hours. The iShares MSCI South Korea ETF (EWY) had 1.2% of its net assets in Celltrion on Aug 31, 2026, according to its Form N-PORT filing. Weights change, so check the fund's holdings page.

What is Celltrion's stock price in US dollars?

Celltrion closed at ₩214,000 in Seoul on Nov 13, 2026, about $159 per share at ₩1,350 per dollar.

What the company does

Celltrion develops, makes and sells biosimilars, close copies of existing biologic drugs. The company says it has global approvals for 11 biosimilars, starting with Remsima (infliximab), which it describes as the world's first antibody biosimilar, and that Zymfentra, an infliximab injected under the skin, won US FDA approval as a new drug in 2023. Biologic drugs were 94% of first-half 2026 revenue.

Celltrion merged with Celltrion Healthcare in December 2023, bringing development, production and sales into one company. The company describes its position in Europe as strong and its US growth as steep. It has 250,000 liters of capacity in Korea and a 66,000-liter US plant in Branchburg, bought in December 2025. Celltrion Holdings owned 25.9% in June 2026.

In July to September 2026, revenue was 53% higher than a year earlier and operating profit 74% higher, according to its corrected preliminary results. Pre-tax profit fell 73%; the filing does not give a reason. In August 2026 Celltrion set a target of returning a third of consolidated net profit to shareholders through dividends and cancelled shares.

Celltrion share price, past year
Seoul closing price; 52-week high on Feb 24, 2026. Tap the chart to enlarge.

Celltrion vs. Teva

Teva (TEVA): We found no close US-listed peer. Sandoz, a closer match in generics and biosimilars, has no NYSE or Nasdaq listing. Teva is shown as a reference: it sells generic drugs and branded medicines as well as biosimilars. Latest quarter (Jul to Sep 2026): revenue $4.4B, GAAP operating margin 16.2%, P/E 101.3x, P/B 6.3x (P/E and P/B at the Nov 11, 2026 close).

For US investors

How to buy Celltrion from the US

Seoul shares (068270)Celltrion has no NYSE or Nasdaq listing. Since May 7, 2026, Interactive Brokers has let eligible clients buy shares listed on the Korea Exchange, which trade in won during Korean hours.
Korea ETFsThe iShares MSCI South Korea ETF (EWY) had 1.2% of its net assets in Celltrion on Aug 31, 2026, before the index change planned for around Nov 9, 2026, according to its Form N-PORT filing. Weights change, so check the fund's holdings page.

Related Korean stocks

Related guides

Sources and notes
  1. Products, capacity, merger, sales channels, customers and shareholders: Celltrion 1H 2026 report (DART, 2026.08.14)
  2. 3Q 2026: Celltrion preliminary consolidated results filed with DART (2026.10.12, corrected 2026.10.27)
  3. Shareholder return target: Celltrion fair disclosure (DART, 2026.08.31)
  4. No NYSE or Nasdaq listing: not in the Nasdaq Trader symbol directory files nasdaqlisted.txt and otherlisted.txt (file of 2026.11.12)
  5. Teva: Form 10-Q for Jul to Sep 2026 and Form 10-K for 2025 (SEC); P/E and P/B from StockAnalysis.com (as of 2026.11.11)
  6. EWY weight: iShares MSCI South Korea ETF, Form N-PORT for Aug 31, 2026 (SEC, filed 2026.10.23); index change: iShares supplement dated Oct 23, 2026 (SEC Form 497), changes "expected to take effect on or around November 9, 2026"
  7. Financials and share count: DART filings (2025 annual report, 1H 2025 and 1H 2026 reports)
  8. Interactive Brokers press release, "Interactive Brokers Launches Access to Korean Equities" (2026.05.07)

Won converted at ₩1,350 per dollar. P/E and P/B use net profit and equity attributable to shareholders; preferred shares, where they exist, are counted with common shares.

For information only, not investment advice. See our full disclaimer.